Eligibility Criteria

Inclusion Criteria:

- Male and female opioid-dependent patients between the ages of 18-65 will be entered
into the study. Females must not be pregnant as determined by pregnancy screening,
nor breast feeding, and must be using acceptable birth control methods during study
participation.

- Current opioid dependence as evidenced by documentation of prior treatment for opioid
dependence or signs of withdrawal, self-reported history of opioid dependence for
consecutive 12 month period and a positive urine for opiates.

- Subjects must fulfill DSM-IV criteria for opioid and cocaine dependence.

- Subjects must have a history of cocaine use, with a reported street cocaine use of a
minimum of 1/2 gram during the preceding 30 days. Additionally, laboratory
confirmation of recent cocaine use (positive urine for cocaine) within 2 weeks prior
to admission to the study is required.

- Subjects must be treatment-seekers for opioid and cocaine use.

Exclusion criteria:

- Current DSM-IV diagnosis of other drug or alcohol dependence (other than opiates,
cocaine, or tobacco)

- History of heart disease, left ventricular hypertrophy, ischemic ECG changes, chest
pain, arrhythmia, hypertension.

- History of severe renal, endocrine or hepatic diseases.

- History of psychosis, schizophrenia, or bipolar type I.

- History of seizure disorder.

- Current use of over-the-counter or prescription psychoactive drugs (antidepressant,
anxiolytics, antipsychotics, mood stabilizers, psychostimulants).

- Liver function tests (SGOT,SGPT) greater than 3 times normal.

- Current use of modafinil

- Current suicidality

- Pregnancy or breast-feeding;

- Medical contraindication to treatment with study medication (e.g. for modafinil,
history of heart disease, ischemic ECG changes, arrhythmia, hypertension).

- Women of child-bearing potential must agree to use other means of birth control and
to have a pregnancy test repeated at least once monthly.

- Known allergy to modafinil or methadone.